



Former Minister of Health Visited MicroPort

On May 27, 2013, Mr. Zhu Chen, the Vice Chairman of NPC Committee and former Minister of Health visited the headquarter of MicroPort along with many other high-ranking national and local governmental officials.

MicroPort Presented at EuroPCR 2013

Paris France, May 22, 2013 -- MicroPort Scientific Corporation (00853.HK) participated at the European Association of Percutaneous Cardiovascular Interventions (EAPCI) which is a registered branch of the European Society of Cardiology (ESC).

MicroPort Orthopedic Suzhou Industrial Base Started Construction

May 19, 2013, MicroPort Orthopedics (Suzhou) Co., Ltd. held its construction ceremony at its project site in Suzhou Singapore Industrial Park.

MicroPort Holding the First Science and Technology Conference

The first Science and Technology Conference hosted by the Shanghai MicroPort Medical (Group) Co., Ltd. was held in Shanghai China from May 10th to 11th.

2nd Shanghai Emerging MediTech Symposium Held in Shanghai

The 2nd Shanghai Emerging MediTech Symposium was held grandly in Shanghai from May 4th to 5th.

Contents

Former Minister of Health Visited MicroPort

MicroPort Presented at EuroPCR 2013

MicroPort Orthopedic Suzhou Industrial Base Started Construction

MicroPort Holding the First Science and Technology Conference

2nd Shanghai Emerging MediTech Symposium Held in Shanghai

Former Minister of Health Visited MicroPort

On May 27, 2013, Mr. Zhu Chen, the Vice Chairman of NPC Committee and former Minister of Health visited the headquarter of MicroPort along with many other high-ranking national and local governmental officials. After a facility tour, the visiting group met the executives of the company and exchanged views on many medical related issues including national and provincial tendering process and reimbursement policies.

[Back to Top](#)

MicroPort Presented at EuroPCR 2013

Paris France, May 22, 2013 -- MicroPort Scientific Corporation (00853.HK) participated at the European Association of Percutaneous Cardiovascular Interventions (EAPCI) which is a registered branch of the European Society of Cardiology (ESC). This year's EuroPCR meeting featured an all-time high turnout. Emerging fields in interventional cardiology research were center stage at the meeting, including various new data and educational sessions detailing the many facets of Drug-Eluting Stent with Bioabsorbable polymer and other percutaneous treatment of high blood pressure and transcatheter aortic valve replacement, among others.

In the morning of May 22, 2013, during the EuroPCR Conference "Innovative Stents and Scaffolds" Session, Mr. Bo Xu, professor from the Chinese National Center for Cardiovascular Disease Fuwai Hospital, presented the latest report on Firehawk® titled "Renaissance of DES, New Generation of Sirolimus-Eluting Stent: The Firehawk® Stent-MicroPort".

Firehawk® Rapamycin Targeted Eluting Coronary Stent ("Firehawk®") is the third generation drug-eluting stent system designed and manufactured exclusively by Shanghai MicroPort Medical (Group) Co., Ltd. The clinical results approved that Firehawk®

is safe and effective. Furthermore it also indicated the feasibility and advantage of the "Targeted Release" feature on Firehawk®. Dr. Run-Lin Gao, C.K.Naber and P.W.Serruys presided over the meeting; G. Cassel, GB Danzi, C. Lotan attended the forum as special guests. The major discussion was about the past development and future trend in the research collaboration in Chinese cardiology field.

The TARGET Trial study compared the Rapamycin Targeted Eluting Coronary Stent (Firehawk®) with conventional everolimus-eluting stent with permanent polymer. The thesis titled "A randomized comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial" was published in the magazine. The overall TARGET study has a non-inferiority design with the primary endpoint of the in-stent late lumen loss at 12 months. Angiographic follow-up showed no major difference in the primary endpoint data and indicated same the feasibility, safety and efficacy between Firehawk® and Xience V.

[Back to Top](#)

MicroPort Orthopedic Suzhou Industrial Base Started Construction

May 19, 2013, MicroPort Orthopedics (Suzhou) Co., Ltd. held its construction ceremony at its project site in Suzhou Singapore Industrial Park. Mr. Hongkun Jiang, Jiangsu Provincial Committee and Party Secretary; Mr. Naixiang Zhou, Suzhou City Mayor; Mr. Guoling Du, Suzhou City Committee member; Mr. Shaodong Wang, Suzhou Municipal Committee Secretary; Mr. Xiang Wang, Suzhou Industrial Park Secretary and other leaders including representatives from MicroPort Group participated the ceremony.

Trauma, spine and joint are the three major categories in orthopedics. According to reports from various sources, by 2015, China will become the world's

second largest market in orthopedic field. Currently, foreign imports in the orthopedics-related products counted more than 70% market share in China. The expectation from MicroPort Orthopedics is high and it has the potential to alter the commercial landscape in orthopedic industry in China.

[Back to Top](#)

MicroPort Holding the First Science and Technology Conference

The first Science and Technology Conference hosted by the Shanghai MicroPort Medical (Group) Co., Ltd. was held in Shanghai China from May 10th to 11th.

The primary purpose of this conference is to bring together MicroPort's scientists, technology developers and specialists from various medical industries in a forum to exchange information on new medical treatment and technology solutions. This exchange of knowledge helps to address issues of design, implementation, and deployment for ideas that are to achieve their research goals in the healthcare industries. The discussion involved a wide range of subjects including cardiovascular, endovascular and neurovascular diseases, orthopedics, endocrinal management and others.

Mr. Qiyi Luo, Chief Technology Officer of the Company, presided over the conference. Participants have come from the private sector, various organizations, and academia. Presentations generally covered technologies for proposed research along with descriptions of indications and approaches that have been proven in the field. Professionals and academia from different hospitals including Zhongshan Hospital, Huashan Hospital, Renji Hospital, Changhai Hospital, Nanjing Military District General Hospital were invited to the conference. The conference helped to facilitate progress in the development of more effective medical products and treatments.

[Back to Top](#)

2nd Shanghai Emerging MediTech Symposium Held in Shanghai

The 2nd Shanghai Emerging MediTech Symposium was held grandly in Shanghai from May 4th to 5th. It was co-sponsored by Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort") and Med-X research institute of SJTU and supported by Shanghai Biomedical Engineering Society.

Dr. Daozhi Liu, senior Vice President of Business Development of MicroPort and Dr. Weihai Yin, Vice President of Biomedical Engineering College of SJTU presided over the symposium. Industry leaders and academian from well-known universities were invited to the event. Participating members include Mr. Guang Ning, Vice President of Shanghai Ruijin Hospital; Mr. Yilin Cao, Vice President of Shanghai Ninth People's Hospital, Mr. Wen Di, Vice President of Shanghai Jiren Hospital; Li Lingsong, Shanghai Advanced Research Institute Stem Cells Nanometer Medical Center of Chinese Academy of Sciences; Mr. Youhua Zhu, Director of Liberation Army Organ Transplantation Research Institute of Shanghai Chang Zheng Hospital and others. The discussed topics involve a variety of subjects including stem cell research, organ transplantation, diagnosis and treatment of diabetes mellitus, infertility and endocrinotherapy. More than 60 professionals coming from business, academic and medical industry attended the symposium.

The goal of the symposium is to establish an open channel of communication between academia and industry, and to encourage mutual sharing of ongoing research results, both successes and failures, so as to facilitate progress in the development of more effective medical products and treatments. The brain storm session brought together scientists and industry leaders from academia, biotechnology and venture capital industry to exchange ideas, disseminate information, and discuss challenges related to the China healthcare industries.

[Back to Top](#)